Vitamin D in human reproduction: a narrative review

2013 ◽  
Vol 67 (3) ◽  
pp. 225-235 ◽  
Author(s):  
Panagiotis Anagnostis ◽  
Spyridon Karras ◽  
Dimitrios G. Goulis
2014 ◽  
Vol 27 (5) ◽  
pp. 483-494 ◽  
Author(s):  
Roberto Russo ◽  
Marinella Ruospo ◽  
Mario Cozzolino ◽  
Luca De Nicola ◽  
Andrea Icardi ◽  
...  

2018 ◽  
Vol 64 (5) ◽  
pp. 1098-1109 ◽  
Author(s):  
Hemant Goyal ◽  
Abhilash Perisetti ◽  
M. Rubayat Rahman ◽  
Avi Levin ◽  
Giuseppe Lippi

2021 ◽  
pp. 113-117
Author(s):  
M.S. Bezerra Espinola ◽  
M. Bertelli ◽  
M. Bizzarri

In late 2019, the new Coronavirus has been identified in the city of Wuhan (China) then COVID-19 spreads like wildfire in the rest of the world. Pregnant women represent a risk category for increased abortion rates and vertical transmission with adverse events on the newborns has been recently confirmed. The scientific world is struggling for finding an effective cure for counteracting symptomatology. Today, there are many therapeutic proposes but none of them can effectively counteract the infection. Moreover, many of these compounds show important side effects not justifying their use. Scientific literature reports an immune system over-reaction through interleukins- 6 activation. In this regard, the possibility to control the immune system represents a possible strategy for counteracting the onset of COVID-19 symptomatology. Vitamin D deficiency shows increased susceptibility to acute viral respiratory infections. Moreover, Vitamin D seems involved in host protection from different virus species by modulating activation and release of cytokines. Myo-inositol down-regulates the expression of IL-6 by phosphatidyl-inositol-3-kinase pathway. Furthermore, myo-inositol is the precursor of phospholipids in the surfactant and it is applied for inducing surfactant synthesis in infants for treating respiratory distress syndrome. This review aims to summarize the evidence about COVID-19 infection in pregnant women and to encourage the scientific community to investigate the use of Vitamin D and Myo-inositol which could represent a possible preventive treatment for pregnant women or women undergoing assisted reproductive technologies.


2021 ◽  
Vol 4 (2) ◽  
pp. 5904-5920
Author(s):  
Janaína Lopes Câmara ◽  
Rogério Rodrigues Vilas Boas ◽  
Luiz Fernando Correa do N. Neto ◽  
Suelen Doriane Gonçalves dos Santos

2019 ◽  
Vol 12 (1) ◽  
pp. 50-59
Author(s):  
Leah Qubty ◽  
Basil Aboul-Enein ◽  
Lori Bechard ◽  
Joshua Bernstein ◽  
Joanna Kruk

PurposeSomalia is an East African nation with a history of civil unrest that produced a significant influx of refugees in the USA in the last 25 years. Between 2000 and 2010, 40 percent of all US Somali refugees settled in Minnesota, which produces new cultural and health challenges for local communities and the state government. One such challenge is vitamin D deficiency, or hypovitaminosis D (Hv-D). Hv-D is developed through insufficient exposure to sunlight and low nutrient intake leading to increased risk for weakness and inflammation, oral health problems, diabetes, cardiovascular and autoimmune diseases and malignancies. The paper aims to discuss these issues.Design/methodology/approachIn this narrative review, demographic, geographic and cultural information about Somali immigration are discussed.FindingsRecent data suggest Somalis living in northern climates (Minnesota, the USA, Helsinki, Finland, Sweden and the UK) experience significant deficiencies in vitamin D. Vitamin D is stimulated by ultraviolet light exposure, a balanced and healthy diet, and dietary supplementation. High unemployment rates affecting access to health information and clinical services, significant cultural differences and climate differences pre-dispose this population to Hv-D. Health education and health promotion programming at the community and state levels in Minnesota should recognize the risk factors associated with Hv-D and the vulnerability of Somali refugees.Originality/valueCurrent and future health programming should be re-assessed for adequate attention to vitamin D deficiency and cultural competency associated with the Somali immigrant population.


2016 ◽  
Vol 31 (7) ◽  
pp. 780-791 ◽  
Author(s):  
G. Michael Allan ◽  
Lynda Cranston ◽  
Adrienne Lindblad ◽  
James McCormack ◽  
Michael R. Kolber ◽  
...  
Keyword(s):  

Maturitas ◽  
2014 ◽  
Vol 79 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Elisabeth Lerchbaum
Keyword(s):  

2021 ◽  
Vol 11 ◽  
Author(s):  
Ana Arnanz ◽  
Neelke De Munck ◽  
Ibrahim El Khatib ◽  
Aşina Bayram ◽  
Andrea Abdala ◽  
...  

ContextThe widespread distribution of the Vitamin D (VitD) receptor in reproductive tissues suggests an important role for VitD in human reproduction. The assessment of patient´s VitD is based on the 25-hydroxyvitamin D (25(OH)D) metabolite measurement. However, most of the circulating 25(OH)D is bound to either VitD-binding protein (VDBP) (88%) or albumin (12%) and less than 1% circulates free.ObjectiveTo determine a possible correlation between VitD levels in serum (S) and follicular fluid (FF) and blastocyst ploidy status in patients undergoing infertility treatment.MethodsA prospective observational study was performed including couples planned for preimplantation genetic testing for aneuploidies (PGT-A) from ART Fertility Clinics. Patients were classified according to their 25(OH)D-Serum levels: VitD deficient group <20 ng/ml and insufficient/replete ≥20 ng/ml defined as VitD non-deficient group.ResultsSerum samples and 226 FF from individual follicles were collected for 25(OH)D, bioavailable 25(OH)D, free 25(OH)D, and % free 25(OH)D measurement. 25(OH)D-Serum in VitD deficient and non-deficient were 13.2±4.0 ng/ml vs 32.3±9.2 ng/ml; p<0.001. FF from 40 and 74 biopsied blastocysts was analysed of which 52.5 and 60.8% were euploid (p = 0.428), respectively. In VitD deficient patients, mean 25(OH)D-FF, bioavailable 25(OH)D-FF, and free 25(OH)D-FF were higher in euploid vs aneuploid blastocysts (18.3±6.3 ng/ml vs 13.9±4.8 ng/ml; p = 0.040; 1.5±0.5 ng/ml vs 1.1±0.4 ng/ml; p = 0.015; 0.005±0.002 ng/ml vs 0.003±0.001 ng/ml; p = 0.023, respectively), whilst no differences were found in VitD non-deficient patients (37.9±12.3 ng/ml vs 40.6±13.7 ng/ml; p = 0.380; 3.1±1.1 ng/ml vs 3.3±1.2 ng/ml; p = 0.323; 0.01±0.003 ng/ml vs 0.01±0.004 ng/ml; p = 0.319, respectively).ConclusionVitD non-deficient patients have a significantly higher probability of obtaining a euploid blastocyst compared to VitD deficient patients (OR:33.36, p = 0.002).


Sign in / Sign up

Export Citation Format

Share Document